These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 23881948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Avastin and Lucentis: a guide through the legal maze.
    Lock D.
    BMJ; 2015 Apr 01; 350():h1377. PubMed ID: 25834023
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Brolucizumab (Beovu) for age-related macular degeneration.
    Med Lett Drugs Ther; 2020 Feb 10; 62(1591):23-24. PubMed ID: 32022789
    [No Abstract] [Full Text] [Related]

  • 15. Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.
    Ahfat FG, Zaidi FH.
    Eye (Lond); 2013 Mar 10; 27(3):289-90. PubMed ID: 23485959
    [No Abstract] [Full Text] [Related]

  • 16. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep 10; 24(163):201-4. PubMed ID: 26417625
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA, Wordsworth S, Rogers CA, Abangma G, Raftery J, Harding SP, Lotery AJ, Downes SM, Chakravarthy U, Reeves BC, IVAN Study Investigators.
    BMJ Open; 2014 Jul 29; 4(7):e005094. PubMed ID: 25079928
    [Abstract] [Full Text] [Related]

  • 18. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.
    Can J Ophthalmol; 2012 Apr 29; 47(2):159-64. PubMed ID: 22560422
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.